Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
Completed · Phase 2
Conditions studied: Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
In brief
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Key facts
- Study ID
- NCT02781584
- Run by
- Gilead Sciences
- People needed
- 220
- Starts
- 2016-06-13
- Expected to finish
- 2020-12-17
- Last updated by the study team
- 2022-03-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Liver Health — Chandler, Arizona, United States
- Altman Clinical and Translational Research Clinic — La Jolla, California, United States
- Ruane Clinical Research Group Inc. — Los Angeles, California, United States
- Cedars-Sinai Medical Center — Los Angeles, California, United States
- Stanford Hospital and Clinics (SHC) — Stanford, California, United States
- Florida Research Institute — Lakewood Rch, Florida, United States
- Delta Research Partners, LLC — Bastrop, Louisiana, United States
- Gastro One — Germantown, Tennessee, United States
- Quality Medical Research — Nashville, Tennessee, United States
- Pinnacle Clinical Research, PLLC — Live Oak, Texas, United States
- American Research Corporation at the Texas Liver Institute — San Antonio, Texas, United States
- Pinnacle Clinical Research, PLLC — San Antonio, Texas, United States
- Auckland Clinical Studies Ltd — Auckland, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.